Immune checkpoint inhibitors include anti-PD-1 or PD-L1 agents (pembrolizumab, nivolumab, avelumab, and durvalumab) and are involved in inhibiting breast cancer, especially the triple-negative subtype when administered as a monotherapy or in combination [30, 31]. This evidence concerns the gene CD274 and breast carcinoma.